RSV Prophylaxis with Palivizumab

Benefits and Limitations

The American Academy of Pediatrics recommends palivizumab for prevention of serious RSV disease in high-risk pediatric populations, with a 55% overall decrease in RSV-related hospitalization in premature infants and those with chronic lung disease 1
Palivizumab provides a 45% decrease in RSV-related hospitalization in infants and children with hemodynamically significant congenital heart disease 1
The medication offers targeted protection during peak RSV season, with the highest circulation of RSV 1, 2
Palivizumab has a well-established safety profile, with adverse events similar to placebo 1
However, palivizumab has not been demonstrated to reduce mortality from RSV infection 1
The medication does not significantly decrease the rate of recurrent wheezing after RSV infection 3
Palivizumab is limited in its scope of protection, only preventing RSV-specific disease, not other respiratory infections 1
The high cost of palivizumab is a consideration, without overall savings in healthcare dollars 1

The recommended dose of palivizumab is 15 mg/kg body weight given monthly by intramuscular injection, with a maximum of 5 doses for most eligible infants 2

Current guidelines recommend palivizumab for infants born before 29 weeks, 0 days' gestation who are younger than 12 months at the start of RSV season 3
Palivizumab may be considered for children younger than 24 months who are profoundly immunocompromised 3
Administration of palivizumab should align with local RSV season patterns, which vary by region 1, 2

The Centers for Disease Control and Prevention recommends RSVpreF vaccine (Abrysvo) as a one-time dose at 32–36 weeks' gestation for prevention of RSV-associated lower respiratory tract disease in infants aged <6 months 4
Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended, but both are not needed for most infants 4